Spine - 2026-11-15 - Journal Article
GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion.
Fano A, Oris RJ, Dalton J, Baidya J, Ng M, Baek G, Tarawneh O, Narayanan R, Huang R, Olson J, Herczeg C, Lee Y, Sellig M, Chua T, Barksdale N, Quiana S, Ponna A, Cronk R, Canseco J, Hilibrand A, Vaccaro A, Kepler C, Schroeder G
Topics
Key Takeaway
Chronic preoperative GLP-1 agonist use in T2DM patients undergoing lumbar fusion was associated with faster return of bowel function (1.35 vs. 1.90 days, p=0.013) without differences in complications, length of stay, or PROMs.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study compared surgical outcomes and PROMs in T2DM patients undergoing primary elective posterior lumbar fusion stratified by chronic preoperative GLP-1 agonist use. GLP-1 users had significantly faster return of bowel function (1.35 vs. 1.90 days, p=0.013), confirmed on Poisson regression as an independent predictor (rate ratio 0.69, p=0.028). No differences were detected in discharge disposition, length of stay, inpatient complications, wound healing, or PROMs between groups.
Key Limitation
The retrospective design with only 117 patients is underpowered to detect differences in low-frequency complications, and the PROMs follow-up duration is not standardized, limiting conclusions about long-term functional equivalence.
Original Abstract
STUDY DESIGN
Retrospective cohort.
OBJECTIVE
To compare surgical outcomes and patient-reported outcome measures (PROMs) after lumbar fusion between type 2 diabetes mellitus (T2DM) patients with versus without chronic preoperative glucagon-like-peptide-1 (GLP-1) receptor agonist use.
SUMMARY OF BACKGROUND DATA
T2DM is a risk factor for adverse outcomes after spine surgery. GLP-1 receptor agonists are increasingly prescribed for patients with T2DM. However, few studies have investigated their impact on lumbar fusion outcomes.
METHODS
T2DM patients undergoing primary, elective posterior lumbar fusion were included; GLP-1 agonist use was identified. Demographic/surgical data were collected by manual chart review. Primary outcomes included surgical outcomes, complications, wound healing, and return of postoperative bowel function. Return of bowel function was defined as flatulence or a bowel movement. Secondary outcomes included PROMs. A Poisson regression predicting the day of postoperative return of bowel function was performed.
RESULTS
Fifty-seven patients had preoperative GLP-1 agonist use, whereas 60 did not. Patients taking GLP-1 agonists were more commonly female (54.4% vs. 30.5%, P =0.016) and had higher mean body mass index (BMI) (34.6±5.96 vs. 32.6±6.08). Otherwise, the groups were demographically/surgically similar. Patients taking GLP-1 agonists demonstrated quicker return of bowel function (1.35±1.30 vs. 1.90±0.77 d, P =0.013). There were no differences in discharge disposition, length of stay, inpatient complications, postoperative wound abnormalities, or PROMs. Regression showed that GLP-1 agonist use independently decreased the time to return of bowel function (rate ratio: 0.69, P =0.028).
CONCLUSIONS
This study suggests that chronic GLP-1 agonist use does not lead to inferior short-term outcomes or long-term PROMs after lumbar fusion. GLP-1 agonists may benefit the return of bowel function, potentially due to chronic gut motility adaptations and/or anti-inflammatory properties. Further study is required to support these findings.